Santen Pharmaceutical (OTCMKTS:SNPHY) Shares Gap Up - Here's What Happened

Key Points

• Shares gapped up — Santen opened at $10.48 after a prior close of $10.025 and last traded at $10.78 on volume of 2,504 shares, about a 5.5% rise.
• Zacks Research upgraded the stock to a "Hold" on April 13, and MarketBeat shows the stock's average analyst rating is currently Hold.
• Company and fundamentals — Santen is a Japan‑based ophthalmology specialist with a market capitalization of $3.40 billion and a reported PE ratio of 0.10, with 50‑day and 200‑day SMAs near $10.96 and $10.67.

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY - Get Free Report) shares gapped up prior to trading on Monday . The stock had previously closed at $10.0250, but opened at $10.48. Santen Pharmaceutical shares last traded at $10.78, with a volume of 2,504 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Santen Pharmaceutical to a "hold" rating in a research note on Monday, April 13th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of "Hold".

Santen Pharmaceutical Stock Up 5.5%

The firm has a market capitalization of $3.40 billion and a PE ratio of 0.10. The firm's fifty day simple moving average is $10.96 and its 200-day simple moving average is $10.67.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.